 UTRECHT, The Netherlands and STAMFORD, Conn., Dec. 17, 2020 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS, a clinical-stage oncology company developing innovative, full-length multi-specific antibodies Biclonics and TriclonicsTM, and Sem a 4, a patient-centered health intelligence company, today announced they have entered into a strategic agreement to utilize Sema4s advanced genomic testing to identify patients with tumors harboring neuregulin 1 gene NRG1 fusions who may be eligible for investigational treatment with the bispecific antibody Zenocutuzumab Zeno in the Phase 12 eNRGy trial sponsored by Merus. 